ArticleBritish journal of clinical pharmacology2020

Withdrawn: Effectiveness and safety of toripalimab, camrelizumab and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients.

Guosheng Yuan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.